Develops microRNA-based therapeutics for metabolic, fibrotic, and orphan diseases.
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering the discovery and development of therapeutics that specifically target microRNAs to address a spectrum of diseases within the United States. At the forefront of its innovative portfolio are promising product candidates such as RG-012, an anti-miR designed to inhibit miR-21, currently undergoing Phase II clinical trials for the treatment of Alport syndrome a severe kidney disease with life-threatening implications.
Additionally, Regulus Therapeutics is advancing RGLS8429, another anti-miR targeting miR-17, currently in Phase 1b clinical studies aimed at treating autosomal dominant polycystic kidney disease, a genetic disorder characterized by cyst formation in the kidneys. Complementing its clinical efforts, the company is actively developing a pipeline of preclinical drug products that employ innovative strategies for organ-selective delivery.
Founded in 2007 and headquartered in San Diego, California, Regulus Therapeutics continues to push the boundaries of biopharmaceutical innovation. With a strategic focus on microRNA-based therapies, the company remains committed to advancing treatments that have the potential to transform the lives of patients facing complex and challenging medical conditions.